Dr. Gregory P. Brandt
Claim this profileSouthern Illinois University School of Medicine
Expert in Tumors
Expert in Lymphoma
40 reported clinical trials
85 drugs studied
About Gregory P. Brandt
Education:
- Earned an MD from Southern Illinois University School of Medicine in 1987.
- Completed Residency in Internal Medicine at the same institution in 1990.
- Finished Fellowship in Gastroenterology at Southern Illinois University School of Medicine in 1992.
Experience:
- Currently serves as a Professor of Medicine at Southern Illinois University School of Medicine, with a specialization in gastroenterology and hepatology.
Area of expertise
1Tumors
Global LeaderStage I
Stage II
Stage IV
2Lymphoma
Global LeaderStage I
Stage II
MTOR positive
Affiliated Hospitals
Clinical Trials Gregory P. Brandt is currently running
Genetic Testing-Directed Therapy
for Pediatric Cancer
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Recruiting1 award Phase 214 criteria
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
More about Gregory P. Brandt
Clinical Trial Related7 years of experience running clinical trials · Led 40 trials as a Principal Investigator · 18 Active Clinical TrialsTreatments Gregory P. Brandt has experience with
- Cyclophosphamide
- Etoposide
- Vincristine Sulfate
- Doxorubicin Hydrochloride
- Laboratory Biomarker Analysis
- Cytology Specimen Collection Procedure
Breakdown of trials Gregory P. Brandt has run
Tumors
Lymphoma
Cancer
Neuroblastoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Gregory P. Brandt specialize in?
Gregory P. Brandt focuses on Tumors and Lymphoma. In particular, much of their work with Tumors has involved Stage I patients, or patients who are Stage II.
Is Gregory P. Brandt currently recruiting for clinical trials?
Yes, Gregory P. Brandt is currently recruiting for 14 clinical trials in Springfield Illinois. If you're interested in participating, you should apply.
Are there any treatments that Gregory P. Brandt has studied deeply?
Yes, Gregory P. Brandt has studied treatments such as Cyclophosphamide, Etoposide, Vincristine Sulfate.
What is the best way to schedule an appointment with Gregory P. Brandt?
Apply for one of the trials that Gregory P. Brandt is conducting.
What is the office address of Gregory P. Brandt?
The office of Gregory P. Brandt is located at: Southern Illinois University School of Medicine, Springfield, Illinois 62702 United States. This is the address for their practice at the Southern Illinois University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.